Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Liposomal Cyclosporine A
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Recipient : Zambon Group SpA
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : L-CsA-i (Liposomal Cyclosporine A) is a novel, inhaled therapy administered via the optimized investigational eFlow® Technology nebulizer system (PARI Pharma GmbH) for the treatment of BOS in adults following single lung (BOSTON-1) or double lung (BOSTO...
Product Name : L-CsA
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 01, 2023
Lead Product(s) : Liposomal Cyclosporine A
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Recipient : Zambon Group SpA
Deal Size : Inapplicable
Deal Type : Inapplicable